Angina Pectoris: Global Drug Forecast and Market Analysis to 2028
Summary
Angina pectoris, or angina for short, refers to chest pain or discomfort caused by insufficient blood supply to the heart muscle, known as myocardial ischemia, when myocardial oxygen demand exceeds oxygen supply. In chronic forms of angina, ischemia of the myocardium can be caused by fixed epicardial coronary artery atherosclerotic obstruction, by microvascular dysfunction (MVD) involving the smaller vessels of the heart, or coronary artery spasm. This report focuses on the following forms of angina: stable angina (atherosclerotic obstruction), microvascular, and variant (also called vasospastic or Prinzmetal angina).
New therapies entering the market will be the main drivers of growth, with one gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 expected to launch in the US during the forecast period. Other major drivers for the angina market are the aging global population, enhanced survival after an MI, and the increasing prevalence of obesity, diabetes, and hypertension. Based on epidemiological analysis by the publisher, the number of diagnosed prevalent cases of stable angina will grow by 16.09% over the forecast period at an AGR of 1.60% from 11,853,368 cases in 2018 to 13,761,123 cases by 2028 in the seven major pharmaceutical markets (7MM) covered in this report, the US, 5EU (France, Germany, Italy, Spain, and UK) and Japan. Diagnosed prevalent cases of microvascular angina will grow by 16.25% from 3,886,426 cases in 2018 to 4,518,109, while variant angina will grow by 16.23% from 49,258 cases in 2018 to 57,255 cases by 2028.
The publisher projects the antianginal drug marketplace for stable, microvascular and variant angina within the 7MM will grow from $2.5B in 2018 at a modest compound annual growth rate (CAGR) of 2.6% to $3.2B by 2028. In particular, the publisher expects the US the US market will contribute the most to the antianginal market’s growth, contributing $1.8B sales in 2018 (72% of the global antianginal market) and $2.5B in 2028 (78% of the global antianginal market).
In terms of the current treatment landscape, the consensus among interviewed physicians was that they have a number of efficacious treatment options at their disposal though there are still patients that are ineffectively managed, and therefore notable unmet needs remain. KOLs interviewed by the publisher highlighted the lack of treatment options targeting refractory patients to be an extremely important unmet need. Another major issue mentioned was the lack of efficacious, evidence-based therapies for microvascular angina. In addition, patients with variant angina also lack treatments tailored to this type of angina, mainly attributed to the knowledge gap in the underlying pathophysiology. Despite a number of drugs currently in development, the publisher’s research suggests that the future level of attainment of these unmet needs will be modest, and a relatively high level of opportunity exists for drug developers to enter the angina market.
Key Highlights
Key Questions Answered
Despite the existence of numerous well-established treatment options in the angina space, a few-yet significant-unmet needs remain.
Scope
Reasons to Buy
The report will enable you to:
Summary
Angina pectoris, or angina for short, refers to chest pain or discomfort caused by insufficient blood supply to the heart muscle, known as myocardial ischemia, when myocardial oxygen demand exceeds oxygen supply. In chronic forms of angina, ischemia of the myocardium can be caused by fixed epicardial coronary artery atherosclerotic obstruction, by microvascular dysfunction (MVD) involving the smaller vessels of the heart, or coronary artery spasm. This report focuses on the following forms of angina: stable angina (atherosclerotic obstruction), microvascular, and variant (also called vasospastic or Prinzmetal angina).
New therapies entering the market will be the main drivers of growth, with one gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 expected to launch in the US during the forecast period. Other major drivers for the angina market are the aging global population, enhanced survival after an MI, and the increasing prevalence of obesity, diabetes, and hypertension. Based on epidemiological analysis by the publisher, the number of diagnosed prevalent cases of stable angina will grow by 16.09% over the forecast period at an AGR of 1.60% from 11,853,368 cases in 2018 to 13,761,123 cases by 2028 in the seven major pharmaceutical markets (7MM) covered in this report, the US, 5EU (France, Germany, Italy, Spain, and UK) and Japan. Diagnosed prevalent cases of microvascular angina will grow by 16.25% from 3,886,426 cases in 2018 to 4,518,109, while variant angina will grow by 16.23% from 49,258 cases in 2018 to 57,255 cases by 2028.
The publisher projects the antianginal drug marketplace for stable, microvascular and variant angina within the 7MM will grow from $2.5B in 2018 at a modest compound annual growth rate (CAGR) of 2.6% to $3.2B by 2028. In particular, the publisher expects the US the US market will contribute the most to the antianginal market’s growth, contributing $1.8B sales in 2018 (72% of the global antianginal market) and $2.5B in 2028 (78% of the global antianginal market).
In terms of the current treatment landscape, the consensus among interviewed physicians was that they have a number of efficacious treatment options at their disposal though there are still patients that are ineffectively managed, and therefore notable unmet needs remain. KOLs interviewed by the publisher highlighted the lack of treatment options targeting refractory patients to be an extremely important unmet need. Another major issue mentioned was the lack of efficacious, evidence-based therapies for microvascular angina. In addition, patients with variant angina also lack treatments tailored to this type of angina, mainly attributed to the knowledge gap in the underlying pathophysiology. Despite a number of drugs currently in development, the publisher’s research suggests that the future level of attainment of these unmet needs will be modest, and a relatively high level of opportunity exists for drug developers to enter the angina market.
Key Highlights
- The proportion of people at risk of developing angina is expected to increase over the 10-year forecast period due to the growing aging population, increased survival after myocardial infarction (MI), and the rise in the prevalence of obesity and diabetes.
- The potential launch of four late-stage pipeline agents will increase the number of patients who can be offered pharmacological treatment options. In addition, three of these drugs in late-stage development are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
- Microvascular angina is being increasingly recognized in clinical practice and there has been a renewed interest among the medical community to understand the pathophysiological mechanisms underpinning its pathogenesis.
- Despite the plethora of therapies currently available to angina patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for refractory patients.
Key Questions Answered
Despite the existence of numerous well-established treatment options in the angina space, a few-yet significant-unmet needs remain.
- Which unmet needs are the most pressing in the 7MM?
- Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?
- What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
- What do KOLs say about their clinical and commercial positioning?
- Which have been historically the companies leading the way?
- What new companies are emerging in the space?
Scope
- Overview of chronic forms of angina pectoris (stable, microvascular, variant) including epidemiology, disease etiology and management.
- Topline angina pectoris drugs market revenue (including antianginals and drugs used for secondary prevention of CV events), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5U and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global angina pectoris therapeutics market. Insightful review of the key industry drivers, restraints and challenges.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global angina pectoris therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global angina pectoris market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global angina pectoris therapeutics market from 2018-2028.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Table of Contents
2 Angina Pectoris: Executive Summary
3 Introduction
4 Disease Overview
5 Epidemiology
7 Competitive Assessment
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Gilead
- Menarini Group
- Ono Pharmaceutical
- Les Laboratoires Servier
- Caladrius Biosciences
- Angionetics
- Milestone Pharmaceuticals
- Imbria Pharmaceuticals
- Astrazeneca
- Bristol-Myers Squibb
- NHS Greater Glasgow and Clyde
